Novartis Ag (NVSEF) Current Deferred Revenue (2017 - 2020)

Novartis Ag has disclosed Current Deferred Revenue across 4 years of filings, most recently posting $56.0 million for Q4 2020.

• Current Deferred Revenue for Q4 2020 came in at $56.0 million, down 50.88% year-over-year; the trailing twelve-month figure through Dec 2020 was $56.0 million (down 50.88% YoY), and the FY2020 annual result was $56.0 million, down 50.88% from the prior year.
• Current Deferred Revenue came in at $56.0 million for Q4 2020 at Novartis Ag, down from $114.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $305.0 million in Q4 2017 to a low of $56.0 million in Q4 2020.
• The 4-year median for Current Deferred Revenue is $175.0 million (2018), against an average of $177.8 million.
• Across the five-year window, Current Deferred Revenue slipped 22.62% in 2018 and tumbled 51.69% in 2019, its largest moves.
• Novartis Ag's Current Deferred Revenue stood at $305.0 million in 2017, then slipped by 22.62% to $236.0 million in 2018, then sank by 51.69% to $114.0 million in 2019, then tumbled by 50.88% to $56.0 million in 2020.
• The last three Current Deferred Revenue figures came in at $56.0 million (Q4 2020), $114.0 million (Q4 2019), and $236.0 million (Q4 2018), per Business Quant data.